---
title: "Gilead Sciences Non-GAAP EPS of $1.90 beats by $0.20, revenue of $7.57B beats by $420M"
date: "2025-02-12 00:03:50"
summary: "Gilead Sciences press release (NASDAQ:GILD): Q4 Non-GAAP EPS of $1.90 beats by $0.20. Revenue of $7.57B (+6.3% Y/Y) beats by $420M. Total fourth quarter 2024 revenue increased 6% to $7.6 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Gilead Sciences [press release](https://seekingalpha.com/pr/19998984-gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results) (NASDAQ:[GILD](https://seekingalpha.com/symbol/GILD "Gilead Sciences, Inc.")): Q4 Non-GAAP EPS of $1.90  beats by $0.20.
* Revenue of $7.57B (+6.3% Y/Y)  beats by $420M.
* Total fourth quarter 2024 revenue increased 6% to $7.6 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology and Liver Disease, partially offset by lower sales of VekluryÂ® (remdesivir).
* FY25 EPS consensus of $7.60
* For the full-year 2025, Gilead expects:
  
  | (in millions, except per share amounts) |  | February 11, 2025 Guidance | | | | | |
  | --- | --- | --- | --- | --- | --- | --- | --- |
  |  | Low End | |  | High End | | |
  | Product sales |  | $ | 28,200 |  | $ | 28,600 |  |
  | Product sales excluding Veklury |  | $ | 26,800 |  | $ | 27,200 |  |
  | Veklury |  | $ | 1,400 |  | $ | 1,400 |  |
  | Diluted EPS |  | $ | 5.95 |  | $ | 6.35 |  |
  | Non-GAAP diluted EPS |  | $ | 7.70 |  | $ | 8.10 |

[seekalpha](https://seekingalpha.com/news/4406400-gilead-sciences-non-gaap-eps-of-1_90-beats-by-0_20-revenue-of-7_57b-beats-by-420m)
